1
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Condition(s):Relapsed/Refractory Peripheral T-cell LymphomaLast Updated:January 31, 2023Recruiting
Anti-PD-1 Monoclonal Antibody: 431 Clinical Trials, Page 1 of 44
Hide Studies Not Open or Pending
2
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer
Condition(s):Breast CancerLast Updated:October 23, 2019Completed
3
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Condition(s):Melanoma; Urological CancerLast Updated:October 22, 2019Unknown status
4
Study of JS001 in Participants With Advanced Solid Tumors
Condition(s):Solid TumorsLast Updated:October 23, 2019Completed
5
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
Condition(s):Advanced Solid TumorsLast Updated:December 2, 2021Active, not recruiting
6
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Condition(s):Colorectal CancerLast Updated:February 1, 2023Not yet recruiting
7
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Condition(s):Advanced Solid Tumours; Cervical Cancer; Malignant Mesothelioma; Lymphoma; Non-Small-Cell Lung CancerLast Updated:April 30, 2021Recruiting
8
Study of JS001 in Patients With Advanced Neuroendocrine Tumors
Condition(s):Neuroendocrine TumorsLast Updated:June 21, 2019Completed
9
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Condition(s):Cancer of Unknown PrimaryLast Updated:April 20, 2022Recruiting
10
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma
Condition(s):Bladder Urothelial CarcinomaLast Updated:September 30, 2020Unknown status